Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Elrig 2018: Drug discovery using small and large molecules

The Drug Target Review team are at Elrig Drug Discovery 2018 in the London ExCel…

Elrig 2018

The Drug Target Review team are attending Elrig 2018 today at the London ExCel. With the event hosting 50 talks over the course of two days, it is the perfect place to be up-to-date with today’s technologies and research.

The initial talk of the day we attended was based on Bicycle Therapeutics in cancer therapy. Dr Gemma Mudd spoke around highly potent and selective tumour targeting bicyclic peptides as a novel approach Ron cancer therapeutics. She spoke of the identification and optimisation of the high affinity bicycle targeting EphA2, and it took only 40 analogues from the initial compound, BCY6009, to the final compound BCY6099. 

Dr Mudd explained how around 70 conjugate toxins were screened before the optimal one was chosen and bound to the compound. The final compound BT5528 maintained efficacy in CDX models. The research team found a significant regression of the tumour after 21 days, at the dose of 3 milligrams per kilogram per week. This compound is now in preclinical trials.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

The talk spoke of novel drug modality and multiple applications of Bicycle molecules. Dr Mudd spoke of the profound efficacy of these compounds, and finished with a question and answer session.

The Drug Target Review team hope to meet more researchers and learn more about the new therapeutics currently in process over the course of the event.